{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:06:09Z","timestamp":1791889569291,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T00:00:00Z","timestamp":1500595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/bcj.2017.65","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T13:21:01Z","timestamp":1500643261000},"page":"e587-e587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Upregulation of TET activity with ascorbic acid induces epigenetic modulation of lymphoma cells"],"prefix":"10.1038","volume":"7","author":[{"given":"N","family":"Shenoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Nieves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Stenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G S","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Habermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Nowakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T E","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,21]]},"reference":[{"key":"BFbcj201765_CR1","doi-asserted-by":"publisher","first-page":"e1003137","DOI":"10.1371\/journal.pgen.1003137","volume":"9","author":"S De","year":"2013","unstructured":"De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M et al. Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS Genet 2013; 9: e1003137.","journal-title":"PLoS Genet"},{"key":"BFbcj201765_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","volume":"3","author":"T Clozel","year":"2013","unstructured":"Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 2013; 3: 1002\u20131019.","journal-title":"Cancer Discov"},{"key":"BFbcj201765_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","volume":"123","author":"O Odejide","year":"2014","unstructured":"Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood 2014; 123: 1293\u20131296.","journal-title":"Blood"},{"key":"BFbcj201765_CR4","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","volume":"120","author":"F Lemonnier","year":"2012","unstructured":"Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood 2012; 120: 1466\u20131469.","journal-title":"Blood"},{"key":"BFbcj201765_CR5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401\u2013404.","journal-title":"Cancer Discov"},{"key":"BFbcj201765_CR6","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood.V128.22.1087.1087","volume":"128","author":"AR Jenny Zhang","year":"2016","unstructured":"Jenny Zhang AR, Love C, Moffitt AB, Rajagopalan D, Lepp\u00e4 S, Pasanen A et al. Integrative genetic and clinical analysis through whole exome sequencing in 1001 diffuse large B cell lymphoma (DLBCL) patients reveals novel disease drivers and risk groups. Blood 2016; 128: 1087.","journal-title":"Blood"},{"key":"BFbcj201765_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13073-015-0134-6","volume":"7","author":"L Scourzic","year":"2015","unstructured":"Scourzic L, Mouly E, Bernard OA . TET proteins and the control of cytosine demethylation in cancer. Genome Med 2015; 7: 9.","journal-title":"Genome Med"},{"key":"BFbcj201765_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature12362","volume":"500","author":"K Blaschke","year":"2013","unstructured":"Blaschke K, Ebata KT, Karimi MM, Zepeda-Martinez JA, Goyal P, Mahapatra S et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013; 500: 222\u2013226.","journal-title":"Nature"},{"key":"BFbcj201765_CR9","doi-asserted-by":"publisher","first-page":"10396","DOI":"10.1021\/ja4028346","volume":"135","author":"R Yin","year":"2013","unstructured":"Yin R, Mao SQ, Zhao B, Chong Z, Yang Y, Zhao C et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 2013; 135: 10396\u201310403.","journal-title":"J Am Chem Soc"},{"key":"BFbcj201765_CR10","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","volume":"19","author":"LJ Hoffer","year":"2008","unstructured":"Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19: 1969\u20131974.","journal-title":"Ann Oncol"},{"key":"BFbcj201765_CR11","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","volume":"18","author":"ME Figueroa","year":"2010","unstructured":"Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553\u2013567.","journal-title":"Cancer Cell"},{"issue":"5","key":"BFbcj201765_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/labinvest.2017.18","volume":"97","author":"Niraj Shenoy","year":"2017","unstructured":"Shenoy N, Stenson M, Lawson J, Abeykoon J, Patnaik M, Wu X et al. Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. Lab Invest 2017; e-pub ahead of print 27 February 2017; doi:10.1038\/labinvest.2017.18.","journal-title":"Laboratory Investigation"},{"key":"BFbcj201765_CR13","doi-asserted-by":"crossref","unstructured":"Shenoy N, Wu X, Witzig T . Protocol modification to determine the cytotoxic potential of drugs using cell viability assays that rely on the reducing property of viable cells. Protoc Exch 2017; e-pub ahead of print 20 March 2017; doi:10.1038\/protex.2017.029.","DOI":"10.1038\/protex.2017.029"},{"key":"BFbcj201765_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008\u20131018.","journal-title":"N Engl J Med"},{"key":"BFbcj201765_CR15","doi-asserted-by":"publisher","first-page":"e309","DOI":"10.1016\/S2352-3026(16)30040-0","volume":"3","author":"PB Johnston","year":"2016","unstructured":"Johnston PB, LaPlant B, McPhail E, Habermann TM, Inwards DJ, Micallef IN et al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol 2016; 3: e309\u2013e316.","journal-title":"Lancet Haematol"},{"key":"BFbcj201765_CR16","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1038\/bcj.2017.57","volume":"7","author":"TE Witzig","year":"2017","unstructured":"Witzig TE, LaPlant B, Habermann TM, McPhail E, Inwards DJ, Micallef IN et al. High rate of event-free survival at 24 months (EFS24) with everolimus\/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance). Blood Cancer J 2017; 7: e576.","journal-title":"Blood Cancer J"},{"key":"BFbcj201765_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/2040620714539906","volume":"5","author":"A Aalipour","year":"2014","unstructured":"Aalipour A, Advani RH . Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib. Therapeut Adv Hematol 2014; 5: 121\u2013133.","journal-title":"Therapeut Adv Hematol"},{"key":"BFbcj201765_CR18","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"Gribben JG, Fowler N, Morschhauser F . Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol 2015; 33: 2803\u20132811.","journal-title":"J Clin Oncol"},{"key":"BFbcj201765_CR19","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952\u20134957.","journal-title":"J Clin Oncol"},{"key":"BFbcj201765_CR20","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","volume":"26","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol 2015; 26: 1667\u20131677.","journal-title":"Ann Oncol"},{"key":"BFbcj201765_CR21","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1111\/febs.13668","volume":"283","author":"G Thanarajasingam","year":"2016","unstructured":"Thanarajasingam G, Thanarajasingam U, Ansell SM . Immune checkpoint blockade in lymphoid malignancies. FEBS J 2016; 283: 2233\u20132244.","journal-title":"FEBS J"},{"key":"BFbcj201765_CR22","doi-asserted-by":"publisher","first-page":"13604","DOI":"10.1073\/pnas.0506390102","volume":"102","author":"Q Chen","year":"2005","unstructured":"Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102: 13604\u201313609.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201765_CR23","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.1073\/pnas.0702854104","volume":"104","author":"Q Chen","year":"2007","unstructured":"Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007; 104: 8749\u20138754.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201765_CR24","doi-asserted-by":"publisher","first-page":"11105","DOI":"10.1073\/pnas.0804226105","volume":"105","author":"Q Chen","year":"2008","unstructured":"Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105: 11105\u201311109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201765_CR25","first-page":"663","volume":"39","author":"E Cameron","year":"1979","unstructured":"Cameron E, Pauling L, Leibovitz B . Ascorbic acid and cancer: a review. Cancer Res 1979; 39: 663\u2013681.","journal-title":"Cancer Res"},{"key":"BFbcj201765_CR26","doi-asserted-by":"publisher","first-page":"10238","DOI":"10.1073\/pnas.1612262113","volume":"113","author":"M Liu","year":"2016","unstructured":"Liu M, Ohtani H, Zhou W, Orskov AD, Charlet J, Zhang YW et al. Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proc Natl Acad Sci USA 2016; 113: 10238\u201310244.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbcj201765_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.rinim.2016.01.001","volume":"6","author":"MJ Huijskens","year":"2016","unstructured":"Huijskens MJ, Wodzig WK, Walczak M, Germeraad WT, Bos GM . Ascorbic acid serum levels are reduced in patients with hematological malignancies. Results Immunol 2016; 6: 8\u201310.","journal-title":"Results Immunol"},{"key":"BFbcj201765_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.2105\/AJPH.94.5.870","volume":"94","author":"JS Hampl","year":"2004","unstructured":"Hampl JS, Taylor CA, Johnston CS . Vitamin C deficiency and depletion in the United States: the Third National Health and Nutrition Examination Survey, 1988 to 1994. Am J Public Health 2004; 94: 870\u2013875.","journal-title":"Am J Public Health"},{"key":"BFbcj201765_CR29","first-page":"443","volume":"1826","author":"J Du","year":"2012","unstructured":"Du J, Cullen JJ, Buettner GR . Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 2012; 1826: 443\u2013457.","journal-title":"Biochim Biophys Acta"},{"key":"BFbcj201765_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.freeradbiomed.2009.02.016","volume":"47","author":"J Verrax","year":"2009","unstructured":"Verrax J, Calderon PB . Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009; 47: 32\u201340.","journal-title":"Free Radic Biol Med"},{"key":"BFbcj201765_CR31","doi-asserted-by":"publisher","first-page":"e29794","DOI":"10.1371\/journal.pone.0029794","volume":"7","author":"DA Monti","year":"2012","unstructured":"Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 2012; 7: e29794.","journal-title":"PLoS One"},{"key":"BFbcj201765_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00280-013-2179-9","volume":"72","author":"CM Stephenson","year":"2013","unstructured":"Stephenson CM, Levin RD, Spector T, Lis CG . Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol 2013; 72: 139\u2013146.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbcj201765_CR33","doi-asserted-by":"publisher","first-page":"222ra18","DOI":"10.1126\/scitranslmed.3007154","volume":"6","author":"Y Ma","year":"2014","unstructured":"Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q . High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 2014; 6: 222ra18.","journal-title":"Sci Transl Med"},{"key":"BFbcj201765_CR34","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1038\/bcj.2016.82","volume":"6","author":"MM Patnaik","year":"2016","unstructured":"Patnaik MM, Zahid MF, Lasho TL, Finke C, Ketterling RL, Gangat N et al. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J 2016; 6: e472.","journal-title":"Blood Cancer J"},{"key":"BFbcj201765_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.hoc.2010.02.007","volume":"24","author":"JP Issa","year":"2010","unstructured":"Issa JP . Epigenetic changes in the myelodysplastic syndrome. Hematol\/oncol clin North Am 2010; 24: 317\u2013330.","journal-title":"Hematol\/oncol clin North Am"},{"key":"BFbcj201765_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1101\/gad.260174.115","volume":"29","author":"KD Rasmussen","year":"2015","unstructured":"Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO et al. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev 2015; 29: 910\u2013922.","journal-title":"Genes Dev"},{"key":"BFbcj201765_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/leu.2013.242","volume":"28","author":"T Schoofs","year":"2014","unstructured":"Schoofs T, Berdel WE, Muller-Tidow C . Origins of aberrant DNA methylation in acute myeloid leukemia. Leukemia 2014; 28: 1\u201314.","journal-title":"Leukemia"},{"key":"BFbcj201765_CR38","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1158\/1078-0432.CCR-14-0494","volume":"20","author":"CY Hu","year":"2014","unstructured":"Hu CY, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharya S et al. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res 2014; 20: 4349\u20134360.","journal-title":"Clin Cancer Res"},{"key":"BFbcj201765_CR39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-015-0180-y","volume":"8","author":"N Shenoy","year":"2015","unstructured":"Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C et al. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol 2015; 8: 88.","journal-title":"J Hematol Oncol"},{"key":"BFbcj201765_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ccr.2013.04.018","volume":"23","author":"E Letouze","year":"2013","unstructured":"Letouze E, Martinelli C, Loriot C, Burnichon N, Abermil N, Ottolenghi C et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013; 23: 739\u2013752.","journal-title":"Cancer Cell"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201765","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bcj.2017.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T17:28:18Z","timestamp":1671730098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,21]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7]]}},"alternative-id":["BFbcj201765"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2017.65","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,21]]},"assertion":[{"value":"1 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}